e10vq
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-Q
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT
OF 1934
FOR THE QUARTERLY PERIOD ENDED
MARCH 31, 2007
Commission File Number 001-16407
ZIMMER HOLDINGS, INC.
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
13-4151777
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(IRS Employer
Identification No.)
|
|
|
|
345 East
Main Street, Warsaw, IN 46580
(Address
of principal executive offices)
Telephone:
(574) 267-6131
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer or a non-accelerated
filer. See definition of accelerated filer and large
accelerated filer in
Rule 12b-2
of the Exchange Act.
Large accelerated
filer þ Accelerated
filer o Non-accelerated
filer o
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange
Act). Yes o No þ
At April 25, 2007, there were 236,776,399 shares
outstanding of the registrants $.01 par value Common
Stock.
ZIMMER
HOLDINGS, INC.
INDEX TO
FORM 10-Q
March 31,
2007
2
Part I
Financial Information
|
|
Item 1.
|
Financial
Statements
|
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
(In
millions, except per share amounts, unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Net Sales
|
|
$
|
950.2
|
|
|
$
|
860.4
|
|
Cost of products sold
|
|
|
206.4
|
|
|
|
189.4
|
|
|
|
|
|
|
|
|
|
|
Gross Profit
|
|
|
743.8
|
|
|
|
671.0
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
52.3
|
|
|
|
47.4
|
|
Selling, general and administrative
|
|
|
361.6
|
|
|
|
334.9
|
|
Acquisition, integration and other
expense (income)
|
|
|
2.7
|
|
|
|
(1.8
|
)
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
416.6
|
|
|
|
380.5
|
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
|
|
327.2
|
|
|
|
290.5
|
|
Interest income (expense)
|
|
|
(0.2
|
)
|
|
|
0.5
|
|
|
|
|
|
|
|
|
|
|
Earnings before income taxes and
minority interest
|
|
|
327.0
|
|
|
|
291.0
|
|
Provision for income taxes
|
|
|
93.3
|
|
|
|
85.1
|
|
Minority interest
|
|
|
(0.3
|
)
|
|
|
(0.3
|
)
|
|
|
|
|
|
|
|
|
|
Net Earnings
|
|
$
|
233.4
|
|
|
$
|
205.6
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Common
Share
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.99
|
|
|
$
|
0.83
|
|
Diluted
|
|
$
|
0.98
|
|
|
$
|
0.82
|
|
Weighted Average Common
Shares Outstanding
|
|
|
|
|
|
|
|
|
Basic
|
|
|
236.9
|
|
|
|
247.8
|
|
Diluted
|
|
|
239.2
|
|
|
|
250.1
|
|
The accompanying notes are an integral part of these
consolidated financial statements.
3
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
(In
millions, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Unaudited)
|
|
|
|
|
|
ASSETS
|
Current Assets:
|
|
|
|
|
|
|
|
|
Cash and equivalents
|
|
$
|
326.0
|
|
|
$
|
265.7
|
|
Restricted cash
|
|
|
2.4
|
|
|
|
2.4
|
|
Accounts receivable, less
allowance for doubtful accounts
|
|
|
692.5
|
|
|
|
625.5
|
|
Inventories, net
|
|
|
658.8
|
|
|
|
638.3
|
|
Prepaid expenses
|
|
|
54.6
|
|
|
|
55.1
|
|
Deferred income taxes
|
|
|
152.3
|
|
|
|
159.2
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,886.6
|
|
|
|
1,746.2
|
|
Property, plant and equipment, net
|
|
|
820.6
|
|
|
|
807.1
|
|
Goodwill
|
|
|
2,466.2
|
|
|
|
2,515.6
|
|
Intangible assets, net
|
|
|
708.9
|
|
|
|
712.6
|
|
Other assets
|
|
|
215.6
|
|
|
|
192.9
|
|
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$
|
6,097.9
|
|
|
$
|
5,974.4
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS EQUITY
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
128.6
|
|
|
$
|
158.0
|
|
Income taxes payable
|
|
|
69.1
|
|
|
|
106.5
|
|
Other current liabilities
|
|
|
401.2
|
|
|
|
363.7
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
598.9
|
|
|
|
628.2
|
|
Other long-term liabilities
|
|
|
280.0
|
|
|
|
323.4
|
|
Long-term debt
|
|
|
100.0
|
|
|
|
99.6
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities
|
|
|
978.9
|
|
|
|
1,051.2
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies
(Note 12)
|
|
|
|
|
|
|
|
|
Minority interest
|
|
|
2.4
|
|
|
|
2.7
|
|
Stockholders
Equity:
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par
value, one billion shares authorized, 250.9 million shares
in 2007 (248.9 million in 2006) issued
|
|
|
2.5
|
|
|
|
2.5
|
|
Paid-in capital
|
|
|
2,870.0
|
|
|
|
2,743.2
|
|
Retained earnings
|
|
|
2,997.1
|
|
|
|
2,768.5
|
|
Accumulated other comprehensive
income
|
|
|
223.3
|
|
|
|
209.2
|
|
Treasury stock, 14.2 million
shares in 2007 (12.1 million in 2006)
|
|
|
(976.3
|
)
|
|
|
(802.9
|
)
|
|
|
|
|
|
|
|
|
|
Total Stockholders
Equity
|
|
|
5,116.6
|
|
|
|
4,920.5
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities and
Stockholders Equity
|
|
$
|
6,097.9
|
|
|
$
|
5,974.4
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
consolidated financial statements.
4
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
(In
millions, unaudited)
|
|
|
|
|
|
|
|
|
|
|
For the Three Months
|
|
|
|
Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Cash flows provided by (used
in) operating activities:
|
|
|
|
|
|
|
|
|
Net earnings
|
|
$
|
233.4
|
|
|
$
|
205.6
|
|
Adjustments to reconcile net
earnings to cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
53.4
|
|
|
|
46.2
|
|
Share-based payment expense
|
|
|
20.9
|
|
|
|
18.2
|
|
Income tax benefit from stock
option exercises
|
|
|
27.9
|
|
|
|
2.0
|
|
Excess income tax benefit from
stock option exercises
|
|
|
(20.0
|
)
|
|
|
(1.8
|
)
|
Changes in operating assets and
liabilities:
|
|
|
|
|
|
|
|
|
Income taxes
|
|
|
18.6
|
|
|
|
26.1
|
|
Receivables
|
|
|
(43.2
|
)
|
|
|
(65.9
|
)
|
Inventories
|
|
|
(19.6
|
)
|
|
|
(13.0
|
)
|
Accounts payable and accrued
expenses
|
|
|
(17.8
|
)
|
|
|
(22.2
|
)
|
Other assets and liabilities
|
|
|
(40.4
|
)
|
|
|
7.5
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating
activities
|
|
|
213.2
|
|
|
|
202.7
|
|
|
|
|
|
|
|
|
|
|
Cash flows provided by (used
in) investing activities:
|
|
|
|
|
|
|
|
|
Additions to instruments
|
|
|
(34.5
|
)
|
|
|
(32.4
|
)
|
Additions to other property, plant
and equipment
|
|
|
(18.7
|
)
|
|
|
(21.5
|
)
|
Proceeds from sale of property,
plant and equipment
|
|
|
|
|
|
|
16.2
|
|
Investments in other assets
|
|
|
(5.9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing
activities
|
|
|
(59.1
|
)
|
|
|
(37.7
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows provided by (used
in) financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from employee stock
compensation plans
|
|
|
58.8
|
|
|
|
11.1
|
|
Excess income tax benefit from
stock option exercises
|
|
|
20.0
|
|
|
|
1.8
|
|
Repurchase of common stock
|
|
|
(173.4
|
)
|
|
|
(7.1
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in)
financing activities
|
|
|
(94.6
|
)
|
|
|
5.8
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash
and equivalents
|
|
|
0.8
|
|
|
|
(0.2
|
)
|
|
|
|
|
|
|
|
|
|
Increase in cash and equivalents
|
|
|
60.3
|
|
|
|
170.6
|
|
Cash and equivalents, beginning of
year
|
|
|
265.7
|
|
|
|
233.2
|
|
|
|
|
|
|
|
|
|
|
Cash and equivalents, end of period
|
|
$
|
326.0
|
|
|
$
|
403.8
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
consolidated financial statements.
5
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
The financial data presented herein is unaudited and should be
read in conjunction with the consolidated financial statements
and accompanying notes included in the 2006 Annual Report on
Form 10-K
filed by Zimmer Holdings, Inc. In the opinion of management, the
accompanying unaudited consolidated financial statements include
all adjustments necessary for a fair statement of the financial
position, results of operations and cash flows for the interim
periods presented. The December 31, 2006 condensed balance
sheet data was derived from audited financial statements, but
does not include all disclosures required by accounting
principles generally accepted in the United States of America.
Results for interim periods should not be considered indicative
of results for the full year. Certain amounts in the three month
period ended March 31, 2006 have been reclassified to
conform to the current year presentation.
The words we, us, our and
similar words refer to Zimmer Holdings, Inc. and its
subsidiaries. Zimmer Holdings refers to the parent company only.
The reconciliation of net earnings to comprehensive income is as
follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
Ended
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Net Earnings
|
|
$
|
233.4
|
|
|
$
|
205.6
|
|
Other Comprehensive Income (Loss):
|
|
|
|
|
|
|
|
|
Foreign currency cumulative
translation adjustments
|
|
|
15.9
|
|
|
|
9.9
|
|
Unrealized foreign currency hedge
losses, net of tax
|
|
|
(7.5
|
)
|
|
|
(5.5
|
)
|
Reclassification adjustments on
foreign currency hedges, net of tax
|
|
|
2.2
|
|
|
|
2.1
|
|
Unrealized gains (losses) on
securities, net of tax
|
|
|
|
|
|
|
0.2
|
|
Change in defined benefit plans,
net of tax
|
|
|
3.5
|
|
|
|
|
|
Minimum pension liability, net of
tax
|
|
|
|
|
|
|
(2.5
|
)
|
|
|
|
|
|
|
|
|
|
Total Other Comprehensive Income
|
|
|
14.1
|
|
|
|
4.2
|
|
|
|
|
|
|
|
|
|
|
Comprehensive Income
|
|
$
|
247.5
|
|
|
$
|
209.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Finished goods
|
|
$
|
499.3
|
|
|
$
|
489.1
|
|
Work in progress
|
|
|
53.9
|
|
|
|
46.4
|
|
Raw materials
|
|
|
105.6
|
|
|
|
102.8
|
|
|
|
|
|
|
|
|
|
|
Inventories, net
|
|
$
|
658.8
|
|
|
$
|
638.3
|
|
|
|
|
|
|
|
|
|
|
6
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
4.
|
Property,
Plant and Equipment
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Land
|
|
$
|
17.6
|
|
|
$
|
17.6
|
|
Buildings and equipment
|
|
|
833.5
|
|
|
|
783.7
|
|
Instruments
|
|
|
799.1
|
|
|
|
768.5
|
|
Construction in progress
|
|
|
69.4
|
|
|
|
105.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,719.6
|
|
|
|
1,675.1
|
|
Accumulated depreciation
|
|
|
(899.0
|
)
|
|
|
(868.0
|
)
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
$
|
820.6
|
|
|
$
|
807.1
|
|
|
|
|
|
|
|
|
|
|
In June 2006, the Financial Accounting Standards Board
(FASB) issued Interpretation No. 48, Accounting
for Uncertainty in Income Taxes an interpretation of
FASB Statement No. 109, Accounting for Income Taxes
(FIN 48). FIN 48 addresses the
determination of whether tax benefits claimed or expected to be
claimed on a tax return should be recorded in the financial
statements. Under FIN 48, we may recognize the tax benefit
from an uncertain tax position only if it is more likely than
not that the tax position will be sustained on examination by
the taxing authorities, based on the technical merits of the
position. The tax benefits recognized in the financial
statements from such a position should be measured based on the
largest benefit that has a greater than fifty percent likelihood
of being realized upon ultimate settlement. FIN 48 also
provides guidance on derecognition, classification, interest and
penalties on income taxes, accounting in interim periods and
requires increased disclosures.
We adopted the provisions of FIN 48 on January 1,
2007. Prior to the adoption of FIN 48 we had a long term
tax liability for expected settlement of various federal, state
and foreign income tax liabilities that was reflected net of the
corollary tax impact of these expected settlements of
$102.1 million, as well as a separate accrued interest
liability of $1.7 million. As a result of the adoption of
FIN 48, we are required to present the different components
of such liability on a gross basis versus the historical net
presentation. The adoption resulted in the financial statement
liability for unrecognized tax benefits decreasing by
$6.4 million as of January 1, 2007. This decrease in
the liability resulted in a reduction to retained earnings of
$4.7 million, a reduction in goodwill of
$61.4 million, the establishment of a tax receivable of
$58.2 million, and an increase in an interest/penalty
payable of $7.9 million, all as of January 1, 2007.
Therefore, after the adoption of FIN 48, the amount of
unrecognized tax benefits is $95.7 million as of
January 1, 2007, of which $28.6 million would impact
our effective tax rate, if recognized. As of March 31,
2007, the amount of unrecognized tax benefits is
$99.6 million, of which $29.6 million would impact our
effective tax rate, if recognized.
We recognize accrued interest and penalties related to
unrecognized tax benefits in income tax expense in the
Consolidated Statements of Earnings, which is consistent with
the recognition of these items in prior reporting periods. As of
January 1, 2007, we recorded a liability of
$9.6 million for accrued interest and penalties, of which
$7.5 million would impact our effective tax rate, if
recognized. As of March 31, 2007, the amount of this
liability is $10.4 million, of which $8.0 million
would impact our effective tax rate, if recognized.
It is expected that the amount of tax liability for unrecognized
tax benefits will change in the next twelve months; however, we
do not expect these changes will have a significant impact on
our results of operations or financial position.
The U.S. federal statute of limitations remains open for
the year 2003 and onward with years 2003 and 2004 currently
under examination by the IRS. It is reasonably possible that a
resolution with the IRS for the years 2003 through 2004 will be
reached within the next twelve months, but we do not anticipate
this would result in any
7
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
material impact on our financial position. In addition, for the
1999 tax year of Centerpulse, which we acquired in October 2003,
one issue remains in dispute at the IRS appeals level. The
resolution of this issue would not impact our effective tax rate
as it would be recorded as an adjustment to goodwill.
State income tax returns are generally subject to examination
for a period of 3 to 5 years after filing of the respective
return. The state impact of any federal changes remains subject
to examination by various states for a period of up to one year
after formal notification to the states. We have various state
income tax returns in the process of examination, administrative
appeals or litigation. It is reasonably possible that such
matters will be resolved in the next twelve months, but we do
not anticipate that the resolution of these matters would result
in any material impact on our results of operations or financial
position.
Foreign jurisdictions have statutes of limitations generally
ranging from 3 to 5 years. Years still open to examination
by foreign tax authorities in major jurisdictions include
Australia (2001 onward), Canada (1998 onward), France (2004
onward), Germany (2000 onward), Italy (2003 onward), Japan (2000
onward), Puerto Rico (2005 onward), Singapore (2002 onward),
Switzerland (2004 onward), and the United Kingdom (2004 onward).
The Company is currently under examination in various foreign
jurisdictions, including France, Germany, Italy and Switzerland.
It is reasonably possible that such audits will be resolved in
the next twelve months, but we do not anticipate that the
resolution of these audits would result in any material impact
on our results of operations or financial position.
|
|
6.
|
Retirement
and Postretirement Benefit Plans
|
We have defined benefit pension plans covering certain U.S. and
Puerto Rico employees who were hired before September 2,
2002. Employees hired after September 2, 2002 are not part
of the U.S. and Puerto Rico defined benefit plans, but do
receive additional benefits under our defined contribution
plans. Plan benefits are primarily based on years of credited
service and the participants compensation. In addition to
the U.S. and Puerto Rico defined benefit pension plans, we
sponsor various
non-U.S. pension
arrangements, including retirement and termination benefit plans
required by local law or coordinated with government sponsored
plans.
We also provide comprehensive medical and group life insurance
benefits to certain U.S. and Puerto Rico retirees who elect to
participate in our comprehensive medical and group life plans.
The medical plan is contributory, and the life insurance plan is
non-contributory. Employees hired after September 2, 2002
are not eligible for retiree medical and life insurance
benefits. No similar plans exist for employees outside the U.S.
and Puerto Rico.
The components of net pension expense for the three month
periods ended March 31, 2007 and 2006, for our U.S. and
non-U.S. defined
benefit retirement plans are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Service cost
|
|
$
|
6.9
|
|
|
$
|
6.0
|
|
Interest cost
|
|
|
3.6
|
|
|
|
3.0
|
|
Expected return on plan assets
|
|
|
(4.5
|
)
|
|
|
(3.6
|
)
|
Amortization of unrecognized
actuarial loss
|
|
|
0.7
|
|
|
|
1.1
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost
|
|
$
|
6.7
|
|
|
$
|
6.5
|
|
|
|
|
|
|
|
|
|
|
8
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The components of net periodic benefit expense for the three
month periods ended March 31, 2007 and 2006, for our U.S.
and Puerto Rico postretirement benefit plans are as follows (in
millions):
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Service cost
|
|
$
|
0.4
|
|
|
$
|
0.5
|
|
Interest cost
|
|
|
0.6
|
|
|
|
0.6
|
|
Amortization of unrecognized prior
service cost
|
|
|
(0.1
|
)
|
|
|
|
|
Amortization of unrecognized
actuarial loss
|
|
|
0.2
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost
|
|
$
|
1.1
|
|
|
$
|
1.3
|
|
|
|
|
|
|
|
|
|
|
We contributed $26.5 million during the three month period
ended March 31, 2007, to our U.S. and Puerto Rico defined
benefit plans and may make contributions of up to a total of
$28 million during 2007. We contributed $2.2 million
to our foreign-based defined benefit plans in the three month
period ended March 31, 2007, and expect to contribute an
additional $7.5 million to these foreign-based plans during
2007. Contributions for the U.S. and Puerto Rico postretirement
benefit plans are not expected to be significant.
|
|
7.
|
Share-Based
Compensation
|
Share-based compensation expense for the three month period
ended March 31, 2007 was $20.9 million, or
$14.3 million net of the related tax benefits. Share-based
compensation expense for the three month period ended
March 31, 2006 was $18.2 million, or
$12.9 million net of the related tax benefits.
A summary of stock option activity for the three month period
ended March 31, 2007 is as follows (options in thousands):
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Weighted Average
|
|
|
|
Options
|
|
|
Exercise Price
|
|
|
Outstanding at January 1, 2007
|
|
|
14,184
|
|
|
$
|
59.75
|
|
Options granted
|
|
|
2,243
|
|
|
|
83.61
|
|
Options exercised
|
|
|
(1,858
|
)
|
|
|
40.64
|
|
Options cancelled
|
|
|
(123
|
)
|
|
|
72.67
|
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2007
|
|
|
14,446
|
|
|
|
65.88
|
|
|
|
|
|
|
|
|
|
|
The weighted-average fair value of the options granted in the
three month period ended March 31, 2007 was $24.66 per
option. As of March 31, 2007, there was $177.5 million
of unrecognized share-based compensation expense related to
nonvested stock options granted under our plans. That expense is
expected to be recognized over a weighted average period of
3.3 years.
At March 31, 2007 and December 31, 2006 there were
905,000 nonvested equity share units, with a grant date fair
value of $67.86. The unrecognized share-based payment expense as
of March 31, 2007 was $17.0 million, and is expected
to be recognized over a period of 1.75 years.
|
|
8.
|
Stock
Repurchase Program
|
In the three month period ended March 31, 2007 we purchased
2,083,800 shares of our common stock at an average price of
$83.18 per share for a total cash outlay of
$173.4 million, including commissions, under a
$1 billion stock repurchase plan authorized by our Board of
Directors in December 2005. An additional $24.0 million may
be purchased under this plan through December 31, 2007. In
December 2006, our Board of Directors authorized an additional
repurchase program of up to $1 billion through
December 31, 2008.
9
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following is a reconciliation of weighted average shares for
the basic and diluted shares computations (in millions):
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
Ended
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Weighted average shares
outstanding for basic net earnings per share
|
|
|
236.9
|
|
|
|
247.8
|
|
Effect of dilutive stock options
|
|
|
2.3
|
|
|
|
2.3
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding for diluted net earnings per share
|
|
|
239.2
|
|
|
|
250.1
|
|
|
|
|
|
|
|
|
|
|
During the three month periods ended March 31, 2007 and
2006, an average of 1.1 million options and
8.9 million options, respectively, to purchase shares of
common stock were not included in the computation of diluted
earnings per share as the exercise prices of these options were
greater than the average market price of the common stock.
We design, develop, manufacture and market reconstructive
orthopaedic implants, including joint and dental, spinal
implants, trauma products and related orthopaedic surgical
products which include surgical supplies and instruments
designed to aid in orthopaedic surgical procedures and
post-operation rehabilitation. We also provide hospital-focused
consulting services to help member institutions design,
implement and manage successful orthpaedic programs. We manage
operations through three major geographic segments
the Americas, which is comprised principally of the United
States and includes other North, Central and South American
markets; Europe, which is comprised principally of Europe and
includes the Middle East and Africa; and Asia Pacific, which is
comprised primarily of Japan and includes other Asian and
Pacific markets. This structure is the basis for our reportable
segment information discussed below. Management evaluates
operating segment performance based upon segment operating
profit exclusive of operating expenses pertaining to global
operations and corporate expenses, share-based payment expense,
acquisition, integration and other expenses, inventory
step-up,
in-process research and development write-offs and intangible
asset amortization expense. Global operations include research,
development engineering, medical education, brand management,
corporate legal, finance, and human resource functions, and U.S.
and Puerto Rico based manufacturing operations and logistics.
Intercompany transactions have been eliminated from segment
operating profit.
10
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Net sales and segment operating profit are as follows (in
millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
|
|
|
Net Sales
|
|
|
Three Months
|
|
|
|
Three Months Ended
|
|
|
Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
Americas
|
|
$
|
567.8
|
|
|
$
|
516.0
|
|
|
$
|
297.0
|
|
|
$
|
268.8
|
|
Europe
|
|
|
258.8
|
|
|
|
228.7
|
|
|
|
112.2
|
|
|
|
99.3
|
|
Asia Pacific
|
|
|
123.6
|
|
|
|
115.7
|
|
|
|
58.5
|
|
|
|
56.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
950.2
|
|
|
$
|
860.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based payment expense
|
|
|
|
|
|
|
|
|
|
|
(20.9
|
)
|
|
|
(18.2
|
)
|
Acquisition and integration
|
|
|
|
|
|
|
|
|
|
|
(2.7
|
)
|
|
|
1.8
|
|
Global operations and corporate
functions
|
|
|
|
|
|
|
|
|
|
|
(116.9
|
)
|
|
|
(117.2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
|
|
|
|
|
|
|
$
|
327.2
|
|
|
$
|
290.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product category net sales are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Reconstructive implants
|
|
$
|
797.5
|
|
|
$
|
717.5
|
|
Trauma
|
|
|
50.1
|
|
|
|
46.7
|
|
Spine
|
|
|
46.7
|
|
|
|
43.1
|
|
Orthopaedic surgical products
|
|
|
55.9
|
|
|
|
53.1
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
950.2
|
|
|
$
|
860.4
|
|
|
|
|
|
|
|
|
|
|
|
|
11.
|
Recent
Accounting Pronouncements
|
In September 2006, the Financial Accounting Standards Board
(FASB) issued Statement of Financial Accountings Standards
(SFAS) No. 157, Fair Value Measurements,
(SFAS No. 157) which defines fair value,
establishes a framework for measuring fair value in generally
accepted accounting principles and expands disclosures about
fair value measurements. This Statement does not require any new
fair value measurements, but provides guidance on how to measure
fair value by providing a fair value hierarchy used to classify
the source of the information. SFAS No. 157 is
effective for financial statements issued for fiscal years
beginning after November 15, 2007. The adoption of
SFAS No. 157 is not expected to have a material impact
on our financial position or results of operations.
In February 2007, the FASB issued SFAS No. 159,
The Fair Value Option for Financial Assets and Financial
Liabilities Including an amendment of FASB Statement
No. 115 (SFAS No. 159).
SFAS No. 159 creates a fair value option
under which an entity may elect to record certain financial
assets or liabilities at fair value upon their initial
recognition. Subsequent changes in fair value would be
recognized in earnings as those changes occur. The election of
the fair value option would be made on a
contract-by-contract
basis and would need to be supported by concurrent documentation
or a preexisting documented policy. SFAS No. 159
requires an entity to separately disclose the fair value of
these items on the balance sheet or in the footnotes to the
financial statements and to provide information that would allow
the financial statement user to understand the impact on
earnings from the changes in the fair value.
SFAS No. 159 is effective for fiscal years beginning
after November 15, 2007. The
11
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
adoption of SFAS No. 159 is not expected to have a
material impact on our financial position or results of
operations.
|
|
12.
|
Commitments
and Contingencies
|
As a result of the Centerpulse acquisition, we acquired the
entity involved in Centerpulses hip and knee implant
litigation matter. The litigation was a result of a voluntary
recall of certain hip and knee implants manufactured and sold by
Centerpulse. On March 13, 2002, a
U.S. Class Action Settlement Agreement
(Settlement Agreement) was entered into by
Centerpulse that resolved U.S. claims related to the
affected products and a settlement trust (Settlement
Trust) was established and funded for the most part by
Centerpulse. The court approved the settlement arrangement on
May 8, 2002. Under the terms of the Settlement Agreement,
we will reimburse the Settlement Trust a specified amount for
each revision surgery over 4,000 and revisions on reprocessed
shells over 64. As of April 2, 2007, the claims
administrator has received 4,133 likely valid claims for hips
(cut-off date June 5, 2003) and knees (cut-off date
November 17, 2003) and 200 claims for reprocessed
shells (cut-off date September 8, 2004). We believe the
litigation liability recorded as of March 31, 2007 is
adequate to provide for any future claims regarding the hip and
knee implant litigation.
On February 15, 2005, Howmedica Osteonics Corp.
(Howmedica) filed an action against us and an
unrelated party in the United States District Court for the
District of New Jersey alleging infringement by the defendants
of U.S. Patent Nos. 6,174,934; 6,372,814; 6,664,308; and
6,818,020. Howmedicas complaint seeks unspecified damages
and injunctive relief. On April 14, 2005, we filed our
answer to the complaint denying Howmedicas allegations.
Discovery is ongoing. We believe that our defenses are valid and
meritorious and we intend to defend the Howmedica lawsuit
vigorously.
We are also subject to product liability and other claims and
lawsuits arising in the ordinary course of business, for which
we maintain insurance, subject to self-insured retention limits.
We establish accruals for product liability and other claims in
conjunction with outside counsel based on current information
and historical settlement information for open claims, related
fees and for claims incurred but not reported. While it is not
possible to predict with certainty the outcome of these cases,
it is the opinion of management that, upon ultimate resolution,
these cases will not have a material adverse effect on our
consolidated financial position, results of operations or cash
flows.
In July 2003, the Staff of the Securities and Exchange
Commission informed Centerpulse that it was conducting an
informal investigation of Centerpulse relating to certain
accounting issues. We are continuing to fully cooperate with the
Securities and Exchange Commission in this matter.
In March 2005, we received a subpoena and we have received
supplemental requests since that time from the United States
Department of Justice through the United States Attorneys
Office in Newark, New Jersey, requesting that we produce
documents and related information for the period beginning
January 1998 pertaining to consulting contracts, professional
service agreements and other agreements by which we may provide
remuneration to orthopaedic surgeons, including research and
other grant agreements. We are cooperating fully with federal
authorities with regard to this matter. We understand that
similar inquiries were directed to at least four other companies
in the orthopaedics industry.
In June 2006, we received a subpoena from the United States
Department of Justice, Antitrust Division, requesting that we
produce documents for the period beginning January 2001 through
June 2006, pertaining to an investigation of possible violations
of federal criminal law, including possible violations of the
antitrust laws, involving the manufacture and sale of
orthopaedic implant devices. We are cooperating fully with
federal authorities with regard to this matter. We understand
that similar inquiries were directed to at least four other
companies in the orthopaedics industry.
Following the commencement of the Department of Justice,
Antitrust Divisions investigation, we and several other
major orthopaedic manufacturers were named as defendants in five
putative class action lawsuits as of January 1, 2007. These
lawsuits were brought by direct and indirect purchasers of
orthopaedic products alleging
12
ZIMMER
HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO
INTERIM CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
violations of Federal and state antitrust laws and certain state
consumer protection statutes. In each of these lawsuits, the
plaintiffs allege that the defendants engaged in a conspiracy to
fix prices of orthopaedic implant devices. The direct purchaser
cases, South Central Surgical Center, LLC v. Zimmer
Holdings, Inc. et al. and Chaiken
DDS, P.C. v. Biomet, Inc. et al., were filed
in the United States District Court for the Southern District of
Indiana on July 13, 2006 and in the United States District
Court for the Northern District of Indiana on July 26,
2006, respectively. The indirect purchaser cases,
Thomas v. Biomet, Inc. et al.,
Kirschner v. Biomet, Inc. et al. and
Williams v. Biomet, Inc. et al., were filed in
the United States District Court for the Western District of
Tennessee on July 18, 2006, July 24, 2006 and
July 27, 2006, respectively.
On January 12, 2007, we and the other defendants in the
five cases delivered a Motion for Transfer and Consolidation of
Pretrial Proceedings under 28 U.S.C. §1407 to the
Judicial Panel on Multidistrict Litigation, requesting the court
to transfer the cases to the United States District Court for
the Southern District of Indiana for coordinated or consolidated
pretrial proceedings. The motion was filed by the Panel on
January 18, 2007. The plaintiffs did not oppose a stay of
proceedings pending resolution of this motion. On
January 15, 2007, the plaintiff in Thomas v.
Biomet, Inc. et al. filed a Notice of Voluntary
Dismissal Without Prejudice in the United States District Court
for the Western District of Tennessee. On April 18, 2007,
the Judicial Panel on Multidistrict Litigation issued a Transfer
Order ordering that the three remaining actions pending outside
the Southern District of Indiana be transferred to that district
for coordinated or consolidated pretrial proceedings with the
action already pending in that district. In each of these four
remaining cases, the plaintiffs seek damages of unspecified
amounts, in some cases to be trebled under applicable law,
attorneys fees and injunctive or other unspecified relief.
We believe these lawsuits are without merit and we intend to
defend them vigorously.
In February 2007, we announced that we would acquire Endius,
Inc., a privately held Massachusetts company, in a cash
transaction. The acquisition was completed in April 2007. The
acquisition is not expected to have a material impact on our
financial position or results of operations.
13
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
Overview
We are a global leader in the design, development, manufacture
and marketing of reconstructive orthopaedic implants, including
joint and dental, spinal implants, trauma products and related
orthopaedic surgical products (sometimes referred to in this
report as OSP). We also provide hospital-focused
consulting services to help member institutions design,
implement and manage successful orthopaedic programs, which
account for less than one percent of sales. Reconstructive
orthopaedic implants restore joint function lost due to disease
or trauma in joints such as knees, hips, shoulders and elbows.
Dental reconstructive implants restore function and aesthetics
in patients that have lost teeth due to trauma or disease.
Spinal implants are utilized by orthopaedic surgeons and
neurosurgeons in the treatment of degenerative diseases,
deformities and trauma in all regions of the spine. Trauma
products are devices used primarily to reattach or stabilize
damaged bone and tissue to support the bodys natural
healing process. OSP includes supplies and instruments designed
to aid in orthopaedic surgical procedures and post-operation
rehabilitation. Through our consulting services, we provide
hospitals and other orthopaedic practices resource capabilities
in the areas of business development, marketing, in/outpatient
rehab practice, clinical pathways, care mapping and space
design, community relations, customer service, delivery models,
cost accounting, staff utilization and other areas. We have
operations in more than 24 countries and market products in more
than 100 countries. We manage operations through three
reportable geographic segments the Americas, Europe
and Asia Pacific.
Certain percentages presented in Managements Discussion
and Analysis are calculated from the underlying whole-dollar
amounts and therefore may not recalculate from the rounded
numbers used for disclosure purposes.
We believe the following developments or trends are important in
understanding our financial condition, results of operations and
cash flows for the three month period ended March 31, 2007.
Demand
(Volume and Mix) Trends
Increased volume and changes in the mix of product sales
contributed 8 percentage points of sales growth, compared
to 7 percentage points in the same 2006 period. We believe
the market for orthopaedic procedure volume on a global basis
continues to rise at mid to high single digit rates driven by an
aging global population, obesity, proven clinical benefits, new
material technologies, advances in surgical techniques (such as
our
Zimmer®
Minimally Invasive Solutions (MIS) Procedures and
Technologies), introduction of gender based devices and more
active lifestyles, among other factors. In addition, the ongoing
shift in demand to premium products, such as
Longevity®
and
Durasul®
Highly Crosslinked Polyethylenes, Trabecular
Metaltm
Technology products, high-flex knees, knee revision products and
porous hip stems, continues to positively affect sales growth.
For example, during the three month period ended March 31,
2007, sales of products incorporating Trabecular Metal
Technology were approximately $51 million, an increase
of over 40 percent compared to the same 2006 period.
We believe innovative products will continue to affect the
orthopaedics industry. In the second half of 2006, we launched
the Zimmer Gender
Solutionstm
High-Flex Knee Femoral Implant, which was the result of five
years of intensive research based on an analysis of 800 femurs
and patella. In the three months ended March 31, 2007, we
sold over 14,000 Gender Solutions Knees, representing an
increase in unit sales of over 50 percent when compared
with the most recent quarter ended December 31, 2006.
Pricing
Trends
Selling prices were flat during the three month period ended
March 31, 2007 compared with a 1 percentage point
increase in average selling prices for the same 2006 period. The
Americas experienced a 1 percent increase in selling prices
during the three month period ended March 31, 2007 compared
with a 2 percent increase for the same 2006 period. In
Europe, selling prices for the three month period ended
March 31, 2007 decreased 1 percent, which is similar
to the same 2006 period. Within Europe, Germany and Italy
experienced 4 percent and 3 percent decreases,
respectively, in selling prices in the three month period ended
March 31, 2007, as a result of reductions in government
implant reimbursement rates and group purchasing arrangements.
Germany and Italy combined represent approximately
11 percent of our sales. Asia Pacific selling prices
decreased 3 percent for the three month
14
period ended March 31, 2007, compared to a less than
1 percent decrease in the same 2006 period. As anticipated,
Japan reported a 6 percent decrease in average selling
prices as a result of scheduled reductions in government
controlled reimbursement prices. Japan represents approximately
7 percent of our sales. With the effect of governmental
healthcare cost containment efforts and pressure from group
purchasing organizations, we expect global selling prices will
remain flat in 2007.
Foreign
Currency Exchange Rates
For the three month period ended March 31, 2007, foreign
currency exchange rates had a positive 2 percent effect on
sales. The positive effect of foreign currency exchange rates
should diminish throughout the year as the weakening of the
U.S. Dollar that we experienced in the third and fourth
quarters of 2006 is anniversaried. We estimate that an overall
weaker U.S. Dollar will have a positive effect of
approximately 1 percent on sales for the year ending
December 31, 2007. We address currency risk through regular
operating and financing activities, and under appropriate
circumstances and subject to proper authorization, through the
use of forward contracts solely for managing foreign currency
volatility and risk. Changes to foreign currency exchange rates
affect sales growth, but due to offsetting gains/losses on hedge
contracts, which are recorded in cost of products sold, the
effect on net earnings in the near term is expected to be
minimal.
New
Product Sales
New products, which management defines as products or stock
keeping units (SKUs) introduced within the
prior
36-month
period to a particular market, accounted for 24 percent, or
$231 million, of our sales during the three month period
ended March 31, 2007. Adoption rates for new technologies
are a key indicator of industry performance. Our sales have
grown with the introduction of new products, such as
Trabecular Metal Modular Acetabular Cups, certain
SKUs of the
NexGen®
Complete Knee Solution including the Gender Solutions
Knee Femoral Implant for the LPS-Flex, and CR-Flex Knees,
the
Dynesys®1
Dynamic Stabilization System, the
Zimmer®
M/L Taper Stem and
PALACOS®2
Bone Cement.
We believe new products in our current pipeline should continue
to favorably affect our operating performance. Products we
expect to contribute to new product sales in 2007 include the
Gender Solutions Knee Femoral Implant; products
incorporating Trabecular Metal Technology, including the
Trabecular Metal Primary Hip Prosthesis, Trabecular
Metal Acetabular Revision System and Trabecular Metal
Spine Components;
Durom®
Acetabular Cups with
Metasul®
LDH®
Large Diameter Heads;
Versys®
Epoch®
Composite Hip Prosthesis;
Zimmer®
Reverse Shoulder System, Anatomical
Shouldertm
Inverse/Reverse System; Zimmer MIS Femoral Nailing
Solutions;
NCB®
Locking Plate System; and CopiOs
®
Bone Void
Filler3.
New
Accounting Pronouncements
On January 1, 2007, we adopted FIN 48. FIN 48
addresses the determination of whether tax benefits claimed or
expected to be claimed on a tax return should be recorded in the
financial statements. Under FIN 48, the tax benefits from
an uncertain tax position may be recognized only if it is more
likely than not that the tax position will be sustained upon
examination by the taxing authorities, based on the technical
merits of the position. FIN 48 also provides guidance on
derecognition, classification, interest and penalties on income
taxes, accounting in interim periods and requires increased
disclosures.
Prior to the adoption of FIN 48, we had a long term tax
liability for expected settlement of various federal, state and
foreign income tax liabilities that was reflected net of the
corollary tax impacts of these expected settlements of
$102.1 million, as well as a separate accrued interest
liability of $1.7 million. As a result of the adoption of
FIN 48, we are required to present the different components
of such liability gross versus the historical net presentation.
The adoption resulted in the tax liability for unrecognized tax
benefits decreasing by $6.4 million as of January 1,
2007.
1 The
Dynesys Dynamic Stabilization Spinal System is indicated
for use as an adjunct to fusion in the U.S.
2 PALACOS®
is a trademark of Heraeus Kulzer GmbH. Under license from
Heraeus Kulzer GmbH, Hanau, Germany.
3 Manufactured
by Kensey Nash Corporation.
15
This decrease in the liability resulted in a reduction to
retained earnings of $4.7 million, a reduction in goodwill
of $61.4 million, the establishment of a tax receivable of
$58.2 million, and the addition of an interest/penalty
payable of $7.9 million, all as of January 1, 2007.
First
Quarter Results of Operations
Net
Sales by Operating Segment
The following table presents net sales by operating segment and
the components of the percentage changes (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
|
|
Volume/
|
|
|
|
|
|
Foreign
|
|
|
|
2007
|
|
|
2006
|
|
|
% Inc (Dec)
|
|
|
Mix
|
|
|
Price
|
|
|
Exchange
|
|
|
Americas
|
|
$
|
567.8
|
|
|
$
|
516.0
|
|
|
|
10
|
%
|
|
|
9
|
%
|
|
|
1
|
%
|
|
|
|
%
|
Europe
|
|
|
258.8
|
|
|
|
228.7
|
|
|
|
13
|
|
|
|
6
|
|
|
|
(1
|
)
|
|
|
8
|
|
Asia Pacific
|
|
|
123.6
|
|
|
|
115.7
|
|
|
|
7
|
|
|
|
9
|
|
|
|
(3
|
)
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
950.2
|
|
|
$
|
860.4
|
|
|
|
10
|
|
|
|
8
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign Exchange as used in the tables in this
report represents the effect of changes in foreign exchange
rates on sales growth.
Net
Sales by Product Category
The following table presents net sales by product category and
the components of the percentage changes (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
|
|
Volume/
|
|
|
|
|
|
Foreign
|
|
|
|
2007
|
|
|
2006
|
|
|
% Inc (Dec)
|
|
|
Mix
|
|
|
Price
|
|
|
Exchange
|
|
|
Reconstructive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Knees
|
|
$
|
407.5
|
|
|
$
|
366.2
|
|
|
|
11
|
%
|
|
|
9
|
%
|
|
|
|
%
|
|
|
2
|
%
|
Hips
|
|
|
316.8
|
|
|
|
292.9
|
|
|
|
8
|
|
|
|
6
|
|
|
|
(1
|
)
|
|
|
3
|
|
Extremities
|
|
|
24.2
|
|
|
|
18.4
|
|
|
|
32
|
|
|
|
29
|
|
|
|
1
|
|
|
|
2
|
|
Dental
|
|
|
49.0
|
|
|
|
40.0
|
|
|
|
22
|
|
|
|
17
|
|
|
|
4
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
797.5
|
|
|
|
717.5
|
|
|
|
11
|
|
|
|
9
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma
|
|
|
50.1
|
|
|
|
46.7
|
|
|
|
7
|
|
|
|
5
|
|
|
|
1
|
|
|
|
1
|
|
Spine
|
|
|
46.7
|
|
|
|
43.1
|
|
|
|
8
|
|
|
|
6
|
|
|
|
1
|
|
|
|
1
|
|
OSP and other
|
|
|
55.9
|
|
|
|
53.1
|
|
|
|
5
|
|
|
|
3
|
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
950.2
|
|
|
$
|
860.4
|
|
|
|
10
|
|
|
|
8
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The NexGen Complete Knee Solution product line including
Gender Solutions Knee Femoral Implants, the NexGen
LPS-Flex Knee, NexGen Trabecular Metal Tibial
Components, the NexGen CR-Flex Knee, the NexGen
Rotating Hinge Knee and the NexGen LCCK Revision Knee
led knee sales. In addition, the
Zimmer®
Unicompartmental High-Flex Knee and the
Innex®
Total Knee System exhibited strong growth.
Growth in porous stems, including the Zimmer M/L Taper
Stem, the
CLS®
Spotorno®
Stem from the CLS Hip System, and the
Alloclassic®
Zweymüller®
Hip Stem led hip stem sales, but were partially offset by weaker
sales of cemented stems. Due to the distribution agreement we
signed to distribute PALACOS Bone Cement, sales of bone
cement improved significantly. Trabecular Metal
Acetabular Cups, Durom Hip Resurfacing System
products internationally, and Longevity and
Durasul Highly Crosslinked Polyethylene Liners also had
strong growth.
16
The
Bigliani/Flatow®
Complete Shoulder Solution and the Trabecular Metal
Humeral Stem led extremities sales. Orthobiologicals and
prosthetic implants, including strong growth of the Tapered
Screw-Vent®
Implant System, led dental sales.
Zimmer®
Periarticular Locking Plates and Zimmer Plates and Screws
led trauma sales. The Dynesys Dynamic Stabilization
System, the
Optimatm4
ZS Spinal Fixation System and Spinal Trabecular Metal
Spacers led spine sales. OSP sales were negatively affected
by the loss of the distribution of the
OrthoPAT®5
Autotransfusion System. Haemonetics Corporation ended an
exclusive distribution agreement with us to sell the
OrthoPAT Autotransfusion System and therefore we were
only able to sell this product through February 2006.
Americas
Net Sales
The following table presents Americas net sales (dollars in
millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
|
|
|
Ended
|
|
|
|
|
|
|
March 31,
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
|
% Inc
|
|
|
Reconstructive
|
|
|
|
|
|
|
|
|
|
|
|
|
Knees
|
|
$
|
262.7
|
|
|
$
|
239.9
|
|
|
|
10
|
%
|
Hips
|
|
|
156.4
|
|
|
|
141.9
|
|
|
|
10
|
|
Extremities
|
|
|
17.7
|
|
|
|
12.9
|
|
|
|
37
|
|
Dental
|
|
|
28.2
|
|
|
|
23.7
|
|
|
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
465.0
|
|
|
|
418.4
|
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma
|
|
|
31.2
|
|
|
|
28.5
|
|
|
|
9
|
|
Spine
|
|
|
38.3
|
|
|
|
36.1
|
|
|
|
6
|
|
OSP and other
|
|
|
33.3
|
|
|
|
33.0
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
567.8
|
|
|
$
|
516.0
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The NexGen Complete Knee Solution product line, including
the Gender Solutions Knee Femoral Implants, NexGen
LPS-Flex Knee, NexGen Trabecular Metal Tibial
Components, the NexGen LCCK Revision Knee and the
NexGen CR-Flex Knee led knee sales. The Zimmer
Unicompartmental High-Flex Knee also made a strong
contribution.
Growth in porous stems, including growth of the Zimmer
M/L Taper Stem and Alloclassic Zweymüller Hip
Stem led hip stem sales, but were partially offset by weaker
sales of cemented stems. PALACOS Bone Cement and
Trabecular Metal Acetabular Cups also exhibited strong
growth.
The Bigliani/Flatow Shoulder Solution and the
Trabecular Metal Humeral Stem led extremities sales. The
Tapered Screw-Vent Implant System led dental sales.
Zimmer Periarticular Plates, Zimmer Plates and
Screws and the I.T.S.T. Intertrochanteric/Subtrochanteric
Fixation System led trauma sales. The Dynesys Dynamic
Stabilization System, the Optima ZS Spinal Fixation
System and Spinal Trabecular Metal Spacers led spine
sales. OSP sales were negatively affected by the loss of the
OrthoPAT Autotransfusion System.
|
|
|
|
4
|
Trademark of U&I Corporation.
|
|
5
|
Registered Trademark of Haemonetics Corporation.
|
17
Europe
Net Sales
The following table presents Europe net sales (dollars in
millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
|
|
|
Ended
|
|
|
|
|
|
|
March 31,
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
|
% Inc
|
|
|
Reconstructive
|
|
|
|
|
|
|
|
|
|
|
|
|
Knees
|
|
$
|
102.0
|
|
|
$
|
88.4
|
|
|
|
16
|
%
|
Hips
|
|
|
113.4
|
|
|
|
103.5
|
|
|
|
10
|
|
Extremities
|
|
|
5.1
|
|
|
|
4.2
|
|
|
|
23
|
|
Dental
|
|
|
13.4
|
|
|
|
11.3
|
|
|
|
18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
233.9
|
|
|
|
207.4
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma
|
|
|
9.0
|
|
|
|
7.8
|
|
|
|
15
|
|
Spine
|
|
|
6.9
|
|
|
|
5.5
|
|
|
|
26
|
|
OSP and other
|
|
|
9.0
|
|
|
|
8.0
|
|
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
258.8
|
|
|
$
|
228.7
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in foreign exchange rates positively affected knee and
hip sales by 9 percent and 8 percent, respectively.
Excluding these foreign exchange rate effects, these product
categories experienced positive sales growth in our Europe
region; the NexGen Complete Knee Solution product line,
including the NexGen LPS-Flex Knee, NexGen Trabecular
Metal Tibial Components and the NexGen CR-Flex Knee,
and the Innex Total Knee System. Growth in porous stems,
including the CLS Spotorno Stem led hip stem sales, but
was offset by weaker sales of cemented and revision stems.
Longevity and Durasul Highly Crosslinked
Polyethylene Liners, the Durom Hip Resurfacing System,
Trabecular Metal Acetabular Cups and the
Allofittm
Hip Acetabular System also contributed to hip sales.
The Anatomical Shoulder System, the Anatomical
Shoulder Inverse/Reverse System and the Coonrad/Morrey Total
Elbow led extremities sales. The Tapered Screw-Vent
Implant System led dental sales. The Cable-Ready
Cable Grip System, Zimmer Periarticular Plates and
the NCB Plating System led trauma sales, which were
offset by weaker sales of our intramedullary fixation systems.
The Dynesys Dynamic Stabilization System, the Optima
ZS Spinal Fixation System and Trabecular Metal
Spacers led spine sales. Wound management products led OSP
sales.
Asia
Pacific Net Sales
The following table presents Asia Pacific net sales (dollars in
millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
|
|
|
|
|
|
|
Ended
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
|
% Inc (Dec)
|
|
|
|
|
|
Reconstructive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Knees
|
|
$
|
42.8
|
|
|
$
|
37.9
|
|
|
|
13
|
%
|
|
|
|
|
Hips
|
|
|
47.0
|
|
|
|
47.5
|
|
|
|
(1
|
)
|
|
|
|
|
Extremities
|
|
|
1.4
|
|
|
|
1.3
|
|
|
|
13
|
|
|
|
|
|
Dental
|
|
|
7.4
|
|
|
|
5.0
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
98.6
|
|
|
|
91.7
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma
|
|
|
9.9
|
|
|
|
10.4
|
|
|
|
(5
|
)
|
|
|
|
|
Spine
|
|
|
1.5
|
|
|
|
1.5
|
|
|
|
(4
|
)
|
|
|
|
|
OSP and other
|
|
|
13.6
|
|
|
|
12.1
|
|
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
123.6
|
|
|
$
|
115.7
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18
Changes in foreign exchange rates positively affected knee sales
by 2 percent and had no effect on hip sales. Reported
decreases in average selling prices negatively affected knee and
hip sales by 1 percent and 5 percent, respectively.
The NexGen Complete Knee Solution product line, including
NexGen Trabecular Metal Tibial Components, the NexGen
CR-Flex Knee and the NexGen LPS-Flex Knee led knee
sales. Launch of the Gender Solutions Knee Femoral
Implant in Australia also contributed to strong knee sales for
the period. The continued conversion to porous stems, including
the Fiber Metal Taper Stem from the
VerSys®
Hip System, the Alloclassic Zweymüller Hip
System and the CLS Spotorno Stem led hip stem sales.
Sales of Longevity and Durasul Highly Crosslinked
Polyethylene Liners, the Durom Hip Resurfacing System and
Trabecular Metal Acetabular Cups also exhibited growth.
Extremities sales increased due to stronger sales of our
shoulder and elbow products. The Tapered Screw-Vent
Implant System led dental sales. Trauma sales were affected
by a reported 5 percent decrease in average selling prices
during the three months ended March 31, 2007. A temporary
registration issue with the
ST360º®
Spinal Fixation System in Japan resulted in a decrease in sales
of this device, contributing to the negative growth in Spine
sales for the period. Powered surgical instruments led OSP sales.
Gross
Profit
Gross profit as a percentage of net sales was 78.3 percent
in the three month period ended March 31, 2007, compared to
78.0 percent in the same 2006 period. Primary contributors
to the improvement in gross profit margin were reductions in
unit manufacturing cost for various products and the effects of
changes in foreign exchange rates combined with our hedging
program. Under our hedging program, for derivatives which
qualify as hedges of future cash flows, the effective portion of
changes in fair value is temporarily recorded in other
comprehensive income, and then recognized in cost of products
sold when the hedged item affects earnings.
Operating
Expenses
R&D as a percentage of net sales was 5.5 percent for
the three month period ended March 31, 2007, consistent
with the same 2006 period. R&D increased to
$52.3 million for the three month period ended
March 31, 2007, from $47.4 million in the same 2006
period, reflecting increased spending on projects focused on
areas of strategic significance, including orthobiologics. We
target R&D spending to the high end of what management
believes to be an average of 4-6 percent for our industry.
SG&A as a percentage of net sales was 38.1 percent for
the three month period ended March 31, 2007, compared to
38.9 percent in the same 2006 period. SG&A increased to
$361.6 million for the three month period ended
March 31, 2007, from $334.9 million in the same 2006
period. SG&A expenses in 2007 were positively affected by
the favorable settlement of a legal claim made against a third
party for interference in a contractual relationship with a
former distributor of our products.
Acquisition, integration and other expenses for the three month
period ended March 31, 2007 were $2.7 million compared
to income of $1.8 million in the same 2006 period. The
expenses for the period reflect estimated settlements for
certain pre-acquisition product liability claims, integration
consulting fees and costs for integrating information technology
systems. The income in the three month period ended
March 31, 2006 was primarily due to a gain on the sale of
our Austin, Texas facility and land and a favorable adjustment
to acquired Centerpulse reserves related to product liabilities.
These were partially offset by an in-process research and
development charge from the purchase of intellectual property
for an intelligent surgical assist device from MedTech S.A.
Operating
Profit, Income Taxes and Net Earnings
Operating profit for the three month period ended March 31,
2007 increased 13 percent to $327.2 million, from
$290.5 million in the same 2006 period. Increased sales,
improved gross profit margins and controlled operating expenses
drove operating profit.
The effective tax rate on earnings before income taxes and
minority interest decreased to 28.5 percent for the three
month period ended March 31, 2007, from 29.3 percent
in the same 2006 period. The decrease in the effective tax rate
is primarily due to increased profitability in lower tax
jurisdictions.
19
Net earnings increased 14 percent to $233.4 million
for the three month period ended March 31, 2007, compared
to $205.6 million in the same 2006 period. The increase was
primarily due to higher operating profit and a lower effective
tax rate. Basic and diluted earnings per share increased
19 percent and 20 percent, respectively, to $0.99 and
$0.98, respectively, from $0.83 and $0.82, respectively, in the
same 2006 period. The higher growth rate in earnings per share
as compared with net earnings is attributed to the effect of
2006 and 2007 share repurchases.
Operating
Profit by Segment
Management evaluates operating segment performance based upon
segment operating profit exclusive of operating expenses
pertaining to global operations and corporate expenses,
share-based payment expense, acquisition, integration and other
expenses, inventory
step-up,
in-process research and development write-offs and intangible
asset amortization expense. Global operations include research,
development engineering, medical education, brand management,
corporate legal, finance, and human resource functions, and
U.S. and Puerto Rico based operations and logistics.
Intercompany transactions have been eliminated from segment
operating profit. For more information regarding our segments,
see Note 10 to the consolidated financial statements
included elsewhere in this
Form 10-Q.
The following table sets forth operating profit as a percentage
of sales by segment for the three month periods ended
March 31, 2007 and 2006:
Percent
of net sales
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Americas
|
|
|
52.3
|
%
|
|
|
52.1
|
%
|
Europe
|
|
|
43.4
|
|
|
|
43.4
|
|
Asia Pacific
|
|
|
47.3
|
|
|
|
48.4
|
|
In the Americas, operating profit as a percentage of sales
increased modestly due to improved gross margins offset by
increased spending for direct to patient advertising.
European operating profit as a percentage of net sales is
consistent with prior year, reflecting slightly lower gross
margins as a result of decreases in average selling prices
offset by a reduction in operating expenses as a percent of
sales.
Asia Pacific operating profit as a percentage of net sales
decreased primarily due to increases in operating expenses as a
percent of sales as compared to the prior year. Operating
expenses grew at a faster rate than sales in Japan where average
selling prices decreased by 6.2 percent as a result of
reductions in government controlled reimbursement prices.
Liquidity
and Capital Resources
Cash flows provided by operating activities were
$213.2 million in 2007, compared to $202.7 million in
the same 2006 period. The principal source of cash was net
earnings of $233.4 million. We had positive cash flows of
$18.6 million from income taxes, primarily related to the
utilization of acquired Centerpulse tax attributes. The positive
cash flow associated with the tax benefit from stock option
exercises was $7.9 million in the three month period ended
March 31, 2007. Operating cash flows from working capital
changes for the three month period ended March 31, 2007
decreased compared to the same 2006 period primarily due to
increased pension funding.
We continue to focus on working capital management. At
March 31, 2007, we had 59 days of sales outstanding in
trade accounts receivable, which is unfavorable to
March 31, 2006, by 2 days. At March 31, 2007, we
had 287 days of inventory on hand, unfavorable to
March 31, 2006 by 2 days and unfavorable to
December 31, 2006 by 10 days. Our inventory levels
have increased due to the preparation for new product launches
and increased production.
20
Cash flows used in investing activities were $59.1 million
in the three month period ended March 31, 2007, compared to
$37.7 million used in investing in the same 2006 period.
Additions to instruments during the three month period ended
March 31, 2007 were $34.5 million, compared to
$32.4 million in the same 2006 period. Additions to other
property, plant and equipment during the three month period
ended March 31, 2007 were $18.7 million, compared to
$21.5 million in the same 2006 period.
Cash flows used in financing activities were $94.6 million
for the three month period ended March 31, 2007, compared
to $5.8 million provided by financing activities in the
same 2006 period. Proceeds from our stock compensation plans
have increased in the three month period ended March 31,
2007, compared to the same 2006 period due to an increase in
employee stock option exercises. For the three months ended
March 31, 2007, we purchased 2.1 million common shares
for a total of $173.4 million as part of a $1 billion
repurchase program, compared to $7.1 million in the same
2006 period.
We have a five year $1,350 million revolving,
multi-currency, senior unsecured credit facility maturing
March 31, 2010 (the Senior Credit Facility). We
had $100.0 million outstanding under the Senior Credit
Facility at March 31, 2007, and therefore, our available
borrowings were $1,250.0 million. The $100.0 million
is owed by our Japan subsidiary and carries a low interest rate,
which is why we have not repaid the debt. The Senior Credit
Facility contains a provision whereby borrowings may be
increased to $1,750 million.
We and certain of our wholly owned foreign and domestic
subsidiaries are the borrowers, and our wholly owned domestic
subsidiaries are the guarantors, of the Senior Credit Facility.
Borrowings under the Senior Credit Facility are used for general
corporate purposes and bear interest at a LIBOR-based rate plus
an applicable margin determined by reference to our senior
unsecured long-term credit rating and the amounts drawn under
the Senior Credit Facility, at an alternate base rate, or at a
fixed rate determined through a competitive bid process. The
Senior Credit Facility contains customary affirmative and
negative covenants and events of default for an unsecured
financing arrangement, including, among other things,
limitations on consolidations, mergers and sales of assets.
Financial covenants include a maximum leverage ratio of 3.0 to
1.0 and a minimum interest coverage ratio of 3.5 to 1.0. If we
fall below an investment grade credit rating, additional
restrictions would result, including restrictions on
investments, payment of dividends and stock repurchases. We were
in compliance with all covenants under the Senior Credit
Facility as of March 31, 2007. Commitments under the Senior
Credit Facility are subject to certain fees, including a
facility and a utilization fee. The Senior Credit Facility was
upgraded to A- in April 2007 by Standard & Poors
Ratings Services. The Senior Credit Facility is not rated by
Moodys Investors Service, Inc.
We also have available uncommitted credit facilities totaling
$65.9 million.
In December 2005, our Board of Directors authorized a stock
repurchase program of up to $1 billion through
December 31, 2007. In December 2006, our Board of Directors
authorized an additional stock repurchase program of up to
$1 billion through December 31, 2008. As of
March 31, 2007, we had purchased shares of common stock
with an aggregate purchase price of $976.3 million,
including commissions. We may use excess cash to purchase
additional common stock under these programs.
Management believes that cash flows from operations, together
with available borrowings under the Senior Credit Facility, are
sufficient to meet our working capital, capital expenditure and
debt service needs. Should investment opportunities arise, we
believe that our earnings, balance sheet and cash flows will
allow us to obtain additional capital, if necessary.
21
Contractual
Obligations
We have entered into contracts with various third parties in the
normal course of business which will require future payments.
The following table illustrates our contractual obligations as
of March 31, 2007, including the adoption of FIN 48
(in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2010
|
|
|
2012
|
|
|
|
|
|
|
|
|
|
and
|
|
|
and
|
|
|
and
|
|
|
|
Total
|
|
|
2007
|
|
|
2009
|
|
|
2011
|
|
|
Thereafter
|
|
|
Long-term debt
|
|
$
|
100.0
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
100.0
|
|
|
$
|
|
|
Operating leases
|
|
|
98.2
|
|
|
|
18.1
|
|
|
|
34.4
|
|
|
|
20.6
|
|
|
|
25.1
|
|
Purchase obligations
|
|
|
32.7
|
|
|
|
31.7
|
|
|
|
1.0
|
|
|
|
|
|
|
|
|
|
Other current tax reserves
|
|
|
10.9
|
|
|
|
10.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities
|
|
|
280.0
|
|
|
|
|
|
|
|
106.7
|
|
|
|
41.6
|
|
|
|
131.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total contractual obligations
|
|
$
|
521.8
|
|
|
$
|
60.7
|
|
|
$
|
142.1
|
|
|
$
|
162.2
|
|
|
$
|
156.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recent
Accounting Pronouncements
In September 2006, the Financial Accounting Standards Board
(FASB) issued Statement of Financial Accountings Standards
(SFAS) No. 157, Fair Value Measurements,
(SFAS No. 157) which defines fair value,
establishes a framework for measuring fair value in generally
accepted accounting principles and expands disclosures about
fair value measurements. This Statement does not require any new
fair value measurements, but provides guidance on how to measure
fair value by providing a fair value hierarchy used to classify
the source of the information. SFAS No. 157 is
effective for financial statements issued for fiscal years
beginning after November 15, 2007. The adoption of
SFAS No. 157 is not expected to have a material impact
on our financial position or results of operations.
In February 2007, the FASB issued SFAS No. 159,
The Fair Value Option for Financial Assets and Financial
Liabilities Including an amendment of FASB Statement
No. 115 (SFAS No. 159).
SFAS No. 159 creates a fair value option
under which an entity may elect to record certain financial
assets or liabilities at fair value upon their initial
recognition. Subsequent changes in fair value would be
recognized in earnings as those changes occur. The election of
the fair value option would be made on a
contract-by-contract
basis and would need to be supported by concurrent documentation
or a preexisting documented policy. SFAS No. 159
requires an entity to separately disclose the fair value of
these items on the balance sheet or in the footnotes to the
financial statements and to provide information that would allow
the financial statement user to understand the impact on
earnings from the changes in the fair value.
SFAS No. 159 is effective for fiscal years beginning
after November 15, 2007. The adoption of
SFAS No. 159 is not expected to have a material impact
on our financial position or results of operations.
Critical
Accounting Estimates
Our financial results are affected by the selection and
application of accounting policies and methods. On
January 1, 2007 we adopted FIN 48. FIN 48
addresses the determination of whether tax benefits claimed or
expected to be claimed on a tax return should be recorded in the
financial statements. Under FIN 48, the tax benefits from
an uncertain tax position may be recognized only if it is more
likely than not that the tax position will be sustained upon
examination by the taxing authorities, based on the technical
merits of the position. FIN 48 also provides guidance on
derecognition, classification, interest and penalties on income
taxes, accounting in interim periods and requires increased
disclosures. FIN 48 requires significant judgment in
determining what constitutes an individual tax position as well
as assessing the outcome of each tax position.
There were no other changes in the three month period ended
March 31, 2007 to the application of critical accounting
estimates as described in our Annual Report on
Form 10-K
for the year ended December 31, 2006.
22
Forward
Looking Statements
This quarterly report contains certain statements that are
forward-looking statements within the meaning of federal
securities laws. When used in this report, the words
may, will, should,
anticipate, estimate,
expect, plan, believe,
predict, potential, project,
target, forecast, intend and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ
materially from those projected. These risks and uncertainties
include, but are not limited to:
|
|
|
|
|
competition;
|
|
|
|
pricing pressures;
|
|
|
|
dependence on new product development, technological advances
and innovation;
|
|
|
|
reductions in reimbursement levels by third-party payors and
cost containment efforts of health care purchasing organizations;
|
|
|
|
the outcome of the pending U.S. Department of Justice
investigations announced in March 2005 and June 2006;
|
|
|
|
challenges relating to changes in and compliance with Federal,
state and foreign governmental laws and regulations affecting
our U.S. and international businesses, including tax
obligations and risks;
|
|
|
|
retention of our independent agents and distributors;
|
|
|
|
changes in customer demand for our products and services caused
by demographic changes or other factors;
|
|
|
|
changes in general domestic and international economic
conditions, including interest rate and currency exchange rate
fluctuations;
|
|
|
|
our ability to protect proprietary technology and other
intellectual property and claims for infringement of the
intellectual property rights of third parties;
|
|
|
|
product liability claims;
|
|
|
|
the possible disruptive effect of additional strategic
acquisitions and our ability to successfully integrate acquired
companies;
|
|
|
|
our ability to form strategic alliances with other orthopaedic
and biotechnology companies;
|
|
|
|
changes in prices of raw materials and products and our ability
to control costs and expenses;
|
|
|
|
changes in general industry and market conditions, including
domestic and international growth rates;
|
|
|
|
our dependence on a limited number of suppliers for key raw
materials and outsourced activities; and
|
|
|
|
shifts in our product category sales mix or our regional sales
mix away from products or geographic regions that generate
higher operating margins.
|
We discuss these and other important risks and uncertainties
that may affect our future operations in Part I,
Item 1A Risk Factors in our most recent Annual
Report on
Form 10-K
and may update that discussion in Part II,
Item 1A Risk Factors in this or another
Quarterly Report on
Form 10-Q
we file hereafter. Readers of this report are cautioned not to
place undue reliance on these forward-looking statements. While
we believe the assumptions on which the forward-looking
statements are based are reasonable, there can be no assurance
that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking
statements contained in this report.
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
There have been no material changes from the information
provided in our Annual Report on
Form 10-K
for the year ended December 31, 2006.
23
|
|
Item 4.
|
Controls
and Procedures
|
We have established disclosure controls and procedures and
internal controls over financial reporting to provide reasonable
assurance that material information relating to us, including
our consolidated subsidiaries, is made known on a timely basis
to management and the Board of Directors. However, no control
system, no matter how well designed and operated, can provide
absolute assurance that the objectives of the control system are
met, and no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if
any, within a company have been detected.
Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness
of the design and operation of our disclosure controls and
procedures (as defined in
Rule 13a-15(e)
of the Securities Exchange Act of 1934) as of
March 31, 2007. Based upon that evaluation, our Chief
Executive Officer and Chief Financial Officer concluded that our
disclosure controls and procedures as of the end of the period
covered by this report are effective.
There was no change in our internal control over financial
reporting (as defined in
Rule 13a-15(f)
of the Securities Exchange Act of 1934) that occurred
during the quarter ended March 31, 2007, that has
materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
Part II
Other Information
|
|
Item 1.
|
Legal
Proceedings
|
Information pertaining to legal proceedings can be found in
Note 12 to the interim consolidated financial statements
included in Part I of this report.
Other than with respect to the risk factor below, there have
been no material changes from the risk factors disclosed in
Part I Item 1A of our Annual Report on
Form 10-K
for the year ended December 31, 2006. The risk factor below
updates the risk factor disclosed in the
Form 10-K
regarding our search for a new Chief Executive Officer.
Our
future success may depend on a successful transition to new
executive leadership.
Effective May 1, 2007, David C. Dvorak, our former Group
President, Global Businesses and Chief Legal Officer, became our
new President and Chief Executive Officer. Our former President
and Chief Executive Officer, J. Raymond Elliott, retired from
these positions effective as of such date, but will continue to
serve as Chairman of the Board of Directors through at least
November 2007. Also effective May 1, 2007, James T. Crines,
our former Senior Vice President, Finance, Operations, and
Corporate Controller and Chief Accounting Officer, became our
new Executive Vice President, Finance and Chief Financial
Officer. Our former Chief Financial Officer resigned to pursue
another business opportunity. We cannot assure you whether these
executives will perform as expected in their new offices or what
effect, if any, their appointment may have on our business and
our ability to retain our other senior executives and key
scientific, technical, sales and marketing employees or the
relationships we have with the independent distributors who
market our products, the orthopaedic surgeons who assist and
advise us and key suppliers and other business partners.
24
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
The following table summarizes repurchases of common stock
settled during the three month period ended March 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number of
|
|
|
Approximate
|
|
|
|
|
|
|
|
|
|
Shares Purchased
|
|
|
Dollar Value of
|
|
|
|
|
|
|
|
|
|
as Part of
|
|
|
Shares that May
|
|
|
|
Total Number
|
|
|
|
|
|
Publicly
|
|
|
Yet Be Purchased
|
|
|
|
of Shares
|
|
|
Average Price
|
|
|
Announced Plans
|
|
|
Under Plans
|
|
|
|
Purchased
|
|
|
Paid per Share
|
|
|
or Programs*
|
|
|
or Programs
|
|
|
January 2007
|
|
|
316,600
|
|
|
$
|
78.87
|
|
|
|
12,462,400
|
|
|
$
|
1,172,390,455
|
|
February 2007
|
|
|
1,185,000
|
|
|
|
83.93
|
|
|
|
13,647,400
|
|
|
|
1,072,938,155
|
|
March 2007
|
|
|
582,200
|
|
|
|
84.00
|
|
|
|
14,229,600
|
|
|
|
1,024,032,907
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
2,083,800
|
|
|
$
|
83.18
|
|
|
|
14,229,600
|
|
|
$
|
1,024,032,907
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* |
|
In December 2005, our Board of Directors authorized the
repurchase of up to $1 billion of common stock through
December 31, 2007. In December 2006, our Board of Directors
authorized the repurchase of an additional $1 billion of
common stock through December 31, 2008. |
|
|
Item 5.
|
Other
Information
|
During the period covered by this report, the Audit Committee of
our Board of Directors approved the engagement of
PricewaterhouseCoopers LLP, our independent registered public
accounting firm, to perform certain tax related services which
represent non-audit services. This disclosure is made pursuant
to Section 10A(i)(2) of the Securities Exchange Act of
1934, as added by Section 202 of the Sarbanes-Oxley Act of
2002.
The following documents are filed as exhibits to this report:
|
|
|
|
|
|
10
|
.1*
|
|
Form of Change in Control
Severance Agreement with James T. Crines and Cheryl R. Blanchard
|
|
31
|
.1
|
|
Certification pursuant to
Rule 13a-14(a)/15d-14(a)
of the Securities Exchange Act of 1934 of the Chief Executive
Officer, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
31
|
.2
|
|
Certification pursuant to
Rule 13a-14(a)/15d-14(a)
of the Securities Exchange Act of 1934 of the Chief Financial
Officer, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
32
|
|
|
Certifications pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
* |
|
Indicates management contract or compensatory plan or
arrangement. |
25
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
ZIMMER HOLDINGS, INC.
(Registrant)
James T. Crines
Executive Vice President, Finance and
Chief Financial Officer
Date: May 7, 2007
26